Case Study

Development And Manufacturing Of A Fab Fragment For Clinical Trials

Laboratory bioprocess iStock-1144377258

Balancing Speed and Risk to Meet an Aggressive Timeline

In this customer case study, we are focusing on our collaboration with Acticor Biotech, a spin-off of Inserm, the French National Institute of Health and Medical Research, which is advancing an innovative drug for the treatment of the acute phase of ischemic stroke.

Acticor selected MilliporeSigma’s BioReliance® End-to-End Solutions for process development and GMP manufacturing of a Fab fragment to support clinical trials. The project timeline allowed only 18 months to get from the cell line to clinical batch manufacturing. A strategic approach to risk management was leveraged to help meet an aggressive timeline.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: